Lanean...
Anti-tumour effect of tocilizumab for osteosarcoma cell lines
AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Sao...
Gorde:
| Argitaratua izan da: | Bone Joint Res |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
The British Editorial Society of Bone & Joint Surgery
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7672325/ https://ncbi.nlm.nih.gov/pubmed/33179539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|